BioCryst Pharmaceuticals (NASDAQ: BCRX) net income
BioCryst Pharmaceuticals reported a net profit of $263.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $88.9m. Its net margin was 30.2%. Earnings per share were $1.26.
Fiscal 2025 is the highest of the 10 fiscal years on record for BioCryst Pharmaceuticals. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $263.9m | — | 30.2% | $1.26 |
| 2024 | −$88.9m | — | −19.7% | −$0.43 |
| 2023 | −$226.5m | — | −68.4% | −$1.18 |
| 2022 | −$247.1m | — | −91.2% | −$1.33 |
| 2021 | −$184.1m | — | −117.1% | −$1.03 |
| 2020 | −$182.8m | — | −1,026.4% | −$1.09 |
| 2019 | −$108.9m | — | −223.0% | — |
| 2018 | −$101.3m | — | −490.3% | — |
| 2017 | −$65.8m | — | −261.2% | — |
| 2016 | −$55.1m | — | −209.3% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
BioCryst Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, BioCryst Pharmaceuticals ranks 79th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of BioCryst Pharmaceuticals, 30.2%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 77th | Innoviva | $271.2m | 65.9% |
| 78th | Chemed | $265.2m | 10.5% |
| 79th | BioCryst Pharmaceuticals | $263.9m | 30.2% |
| 80th | Insulet | $247.1m | 9.1% |
| 81st | Alkermes | $241.7m | 16.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of BioCryst Pharmaceuticals
- How much did BioCryst Pharmaceuticals earn in fiscal 2025?
- BioCryst Pharmaceuticals reported a net profit of $263.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $88.9m.
- What are the earnings per share of BioCryst Pharmaceuticals?
- They were $1.26 in fiscal 2025, compared with −$0.43 in fiscal 2024.
- What is the net margin of BioCryst Pharmaceuticals?
- In fiscal 2025 its net profit was 30.2% of its revenue.
- What was the most profitable year for BioCryst Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $263.9m.
- Where does BioCryst Pharmaceuticals rank in its sector by net income?
- It ranks 79th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for BioCryst Pharmaceuticals come from?
- From the annual report (Form 10-K) that BioCryst Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that BioCryst Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on BioCryst Pharmaceuticals: the BioCryst Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.